Accounting Financial Analysis Report

Running head: ACCOUNTING FINANCIAL ANALYSIS REPORT
Accounting Financial Analysis Report
Name of the Student:
Name of the University:
Authors Note:

ACCOUNTING FINANCIAL ANALYSIS REPORT
1
Table of Contents
Financial performance of Bristol Myers Squibb and Eli Lilly:..................................................2
Recommendation for investing in Bristol Myers Squibb and Eli Lilly:....................................4
Conclusion:................................................................................................................................4
References:.................................................................................................................................5

ACCOUNTING FINANCIAL ANALYSIS REPORT
2
Financial performance of Bristol Myers Squibb and Eli Lilly:
Bristol-Myers Squibb
Particulars 2017 2016
Revenue 20,776 19,427
Gross profit 14,710 14,481
Net profit 1,007 4,457
Current assets 14,854 13,704
Inventory 1,166 1,241
Current liabilities 9,563 8,841
Net profit Margin 4.85% 22.94%
Gross profit Margin 70.80% 74.54%
Current Ratio 1.55 1.55
Quick Ratio 1.43 1.41
From the overall evaluation of the above table the financial performance of Bristol-
Myers Squibb could be identified, which help investors in making adequate investment
decisions. In addition, the profitability and liquidity ratio has mainly helped in understanding
the level of financial performance, which could help in detecting investment opportunity for
the investors (Atoom, Malkawi & Al Share, 2017). The net profit margin of Bristol-Myers
Squibb has mainly declined from 22.94% in 2016 to 4.85% in 2017, which relevantly
indicates the low financial capability of the organisation. Furthermore, the gross profit margin
of the organisation has also declined from the level of 74.54% in 2016 to 70.80% in 2017,
which indicates the relevant decline in profits of the organisation. In addition, the liquidity